Home > Resources > Company Profiles > GlaxoSmithKline PLC

GlaxoSmithKline PLC (GSK)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Enter the text you see in the image *

Letters are not case-sensitive, disregard spaces.

Try a New One

This helps us prevent automated registrations and spamming.

Email Confirmation

Andrew Witty , Divisional President/Director/CEO

www.gsk.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

The Company and its subsidiary is engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products.

Portfolio Articles

Just What the Doctor Ordered
GlaxoSmithKline and Eli Lilly break with the rest of the drug industry on pricing and on disclosing studies and doctors' perks.
May 21 2008
The Ultimare Cure
The neurotech industry is engaged in a $2 trillion race to fix your brain. Many players will fail, but the payoff will be huge for those who succeed.
May 12 2008
Fountain of Money
Sirtris Pharmaceuticals and its novel drugs to combat age-related diseases and to increase life span are snatched up by GlaxoSmithKline for $720 million.
Apr 23 2008
Dollar Daze
Weakling currency is pummeling European companies in the U.S.
Oct 17 2007
Passing the Glaxo Drug Test
Pharmaceutical giant picks its next C.E.O.
Oct 08 2007

See more news on this company

News Feeds

GlaxoSmithKline, Harvard agree to $25M stem-cell deal Raleigh / Durham
Jul 24 2008
NuPathe raises $30M from Quaker BioVentures and others Philadelphia
Jul 24 2008
GlaxoSmithKline 2Q profit slips on competition AP
Jul 23 2008
GlaxoSmithKline 2Q earnings hurt by generics, Avandia Pittsburgh
Jul 23 2008
Earnings roundup: NY Times, GlaxoSmithKline AP
Jul 23 2008
Top drug companies' earnings beat forecasts Reuters
Jul 23 2008
GlaxoSmithKline earnings hurt by generics, Avandia Raleigh / Durham
Jul 23 2008
Glaxo to invest in diversity, cautious on outlook Reuters
Jul 23 2008
Glaxo to sell branded generics in emerging markets Reuters
Jul 23 2008
Dollar, cost cuts help Novartis Q2 beat forecast Reuters
Jul 17 2008

Portfolio Blogs

Do Antidepressants Prevent Suicides?
Apr 10 2008

Press Releases

POZEN to Present at the 2008 BMO Capital Markets Focus on Healthcare Conference Jul-24-2008, 11:30AM EDT
Apriso to Moderate MES Panel Discussion Jul-24-2008, 10:57AM EDT
Adolor Provides Entereg(R) (Alvimopan) Hospital Registration Update Jul-24-2008, 07:30AM EDT
GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO Jul-23-2008, 11:06AM EDT
Teva Introduces First Generic Lamictal(R) Tablets in the United States Jul-22-2008, 11:11AM EDT

News From Around the Web

News

Glaxo Says, 'Lights, Camera, Action!' (Wall Street Journal Health Blog)

Jul 26 2008
Generics? No Thanks, We're Glaxo (Wall Street Journal Health Blog)

Jul 26 2008
FDA Wants Testing for Diabetes Drugs (Sci-Tech Today)

Jul 25 2008
Income Investor: GlaxoSmithKline Turning Toward Simpler Strategy (Investors Business Daily)

Jul 25 2008
Glaxo Changes Course (Motley Fool)

Jul 25 2008
F.D.A. Urges Genetic Test Before Giving AIDS Drug (Sarasota Herald Tribune)

Jul 25 2008
Glaxo commits $25 million to Harvard Stem Cell Institute (Boston Business Journal)

Jul 25 2008
GlaxoSmithKline, Harvard agree to $25M stem-cell deal (Triangle Business Journal)

Jul 25 2008
Harvard stem cell research gets boost (Boston Globe)

Jul 25 2008
Glaxo peddles Aspen (Business Day, South Africa)

Jul 25 2008

Blogs

Glaxo Cuts More Jobs At North Carolina Plant (Pharmalot)

Jul 25 2008
In Australia, Pfizer Is Guilty Of Discrediting Pharma (Pharmalot)

Jul 25 2008
Lilly, Pfizer & The Economies of ED (CNBC: Pharmas Market with Mike Huckman)

Jul 24 2008
Glaxo AIDS Drug Will Require Genetic Testing (Pharmalot)

Jul 24 2008
GSK do have a plan - "More growth with less risk" (PharmaGossip)

Jul 24 2008

Employees

Number of Employees: 103,000

Revenue per Employee: $455,514

Top Executives

Marc Dunoyer, Divisional President

Eddie Gray, President, Divisional

Dr. Russell Greig, Divisional President

John Clarke, Divisional President

Julian Heslop, CFO/Director

Bill Louv, Chief Information Officer

Dan Phelan, Divisional Senior VP

Christopher Viehbacher, Divisional President/Director

Duncan Learmouth, Senior VP, Divisional

Dr. David Pulman, Divisional President

Board of Directors

Dr. Stephanie Burns, Ph.D., Director

Dr. Daniel Podolsky, Director

Sir Robert Wilson, Director

Simon Bicknell, Secretary

Sir Ian Prosser, Director

Sir Crispin Davis, Director

Sir Christopher Gent, Chairman of the Board/Director

Dr.Ronaldo H. Schmitz, Director

Dr. Moncef Slaoui, Ph.D., Chairman of the Board, Divisional/Director

Julian Heslop, CFO/Director

Tom de Swaan, Director

Lawrence Culp, Director

Sir Deryck Maughan, Director

Christopher Viehbacher, Divisional President/Director

Professor Sir Roy Anderson, Director

Financials

Quarterly

Annual

Income Statement	04/2008	02/2008	10/2007	07/2007
Sales	1.96 Bil.	2.49 Bil.	1.69 Bil.	1.92 Bil.
Gross Operating Profit	9.32 Bil.	9.37 Bil.	9.51 Bil.	9.47 Bil.
Operating Income before D & A (EBITDA)	4.36 Bil.	3.68 Bil.	4.63 Bil.	4.19 Bil.
Total Income Before Interest Expenses (EBIT)	4.09 Bil.	3.28 Bil.	4.09 Bil.	4.05 Bil.
Total Net Income	2.59 Bil.	2.1 Bil.	2.68 Bil.	2.68 Bil.
Basic EPS, Total	0.97	0.78	0.97	0.96
Diluted EPS, Total	0.97	0.78	0.97	0.95

BALANCE STATEMENT	04/2008	02/2008	10/2007	07/2007
Cash and Equivalents	4.26 Bil.	6.71 Bil.	4.19 Bil.	3.8 Bil.
Total Assets	24.86 Bil.	27.05 Bil.	23.28 Bil.	22.03 Bil.
Total Liabilities	18.4 Bil.	20.54 Bil.	18.47 Bil.	14.47 Bil.
Total Capitalization	33.78 Bil.	33.09 Bil.	30.2 Bil.	31.76 Bil.

Cash Flow	04/2008	02/2008	10/2007	07/2007
Net Cash From Continuing Operations	3.57 Bil.	12.23 Bil.	9.77 Bil.	5.89 Bil.
Net Cash From Investing Activities	-468 Mil.	-5.97 Bil.	-3.34 Bil.	-2.57 Bil.
Net Cash From Financing Activities	-5.6 Bil.	-3.46 Bil.	-6.61 Bil.	-3.66 Bil.
Net Change in Cash & Cash Equivalents	-2.51 Bil.	2.8 Bil.	-172 Mil.	-371 Mil.

Income Statement	2008	2007	2006	2005
Sales	7.91 Bil.	7.94 Bil.	6.64 Bil.	6.55 Bil.
Gross Operating Profit	37.18 Bil.	37.55 Bil.	30.62 Bil.	32.48 Bil.
Operating Income before D & A (EBITDA)	16.78 Bil.	16.57 Bil.	12.75 Bil.	13.5 Bil.
Total Income Before Interest Expenses (EBIT)	15.69 Bil.	15.89 Bil.	12.36 Bil.	12.32 Bil.
Total Net Income	10.35 Bil.	10.56 Bil.	8.07 Bil.	8.25 Bil.
Basic EPS, Total	3.75	3.74	3	2.88
Diluted EPS, Total	3.75	3.7	3	2.87

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	6.71 Bil.	3.93 Bil.	7.24 Bil.	2.23 Bil.
Total Assets	27.05 Bil.	21.53 Bil.	22.67 Bil.	26.14 Bil.
Total Liabilities	20.54 Bil.	14.23 Bil.	16.36 Bil.	16.72 Bil.
Total Capitalization	33.09 Bil.	27.54 Bil.	21.64 Bil.	19.76 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	12.23 Bil.	8.53 Bil.	10.25 Bil.	9.02 Bil.
Net Cash From Investing Activities	-5.97 Bil.	-2.98 Bil.	-2.86 Bil.	-2.12 Bil.
Net Cash From Financing Activities	-3.46 Bil.	-9.39 Bil.	-5.01 Bil.	-7.54 Bil.
Net Change in Cash & Cash Equivalents	2.8 Bil.	-4.33 Bil.	2.78 Bil.	-644 Mil.

GlaxoSmithKline PLC (GSK)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request